Form D · Biotechnology

Nora Therapeutics, Inc.

Palo Alto, CA · CIK 0001461695

Offering snapshot reported Oct 13, 2015 · SEC filing

Reported sold
$1M
Offering amount: $3M
Investors reported
6
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Sep 29, 2015
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 13, 2015Initial$1,000,000No comparison6SEC filing
May 14, 2015InitialYet to sellNo comparison1SEC filing
Apr 23, 2014Initial$18,000,000No comparison6SEC filing
Sep 23, 2010Initial$14,880,000No comparison5SEC filing
Jun 2, 2010Amendment$2,932,000$1,932,000vs Apr 13, 20094SEC filing
Apr 13, 2009Initial$1,000,000No comparisonNot reportedSEC filing

Offering details

Securities
Debt, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-249197

Source: Form D, filed Oct 13, 2015. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Darryl L. Carter Executive
Alan Colowick Director, Executive
Anupam Dalal Director
Dennis Fenton Director
Bryant E. Fong Director
Donald Hayden, Jr. Director
Christopher B. Mc Clain Executive
Julie Mc Hugh Director, Executive
David Schnell Director
Jeffrey K. Tong Director, Executive
Joseph L. Turner, Jr. Director
Martin Vogelbaum Director
Chen Yu Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
530 Lytton Avenue, 2 Nd Floor
Palo Alto, CA, 94301